News and Trends 8 Dec 2022 New method uses metabolism to detect cancers When cancer is detected at an early stage, the rates of survival increase drastically, but today only a few cancer types are screened for. An international study led by researchers from Chalmers University of Technology, Sweden, shows that a new, previously untested method can easily find multiple types of newly formed cancers at the same […] December 8, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2022 Laevoroc Oncology pushes for relapsed leukemia cure Laevoroc Oncology, a privately-owned, Swiss oncology development company, has announced the publication of key preclinical data carried out at the University of California, Los Angeles (UCLA), which provides mechanistic insights into the immunoregulatory functions of purine nucleoside phosphorylase (PNP) with Laevoroc’s PNP inhibitor, LR 09. The research shows that PNP is a novel metabolic immune […] December 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2022 DNA repair mechanism study could boost cancer treatment A better understanding of the mechanisms involved in DNA repair may pave the way for developing inhibitors to improve the effectiveness of radiation therapy. Nucleotide excision repair (NER) is a critical DNA repair pathway that plays a key role in maintaining transcription and genome integrity by removing bulky DNA lesions. The key steps in the […] December 8, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2022 Ibex and Source announce agreement to aid pathologists with diagnostic accuracy An agreement has been announced between Ibex Medical Analytics and Source LDPath, part of Source BioScience. It will expand the deployment of artificial intelligence (AI) to Source’s entire pathology network. Ibex works with AI-powered cancer diagnostics and the expansion builds on its previous work with LDPath. Source, which provides integrated laboratory services and products, acquired […] December 7, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2022 Touchlight and Odimma Therapeutics sign deal to develop personalized cancer therapy Touchlight, a biotechnology company pioneering enzymatic DNA production to enable genetic medicines, has signed a development and supply agreement with Odimma Therapeutics, a French biotech company focusing on personalized cancer immunotherapy. The agreement focuses on the provision of clinical material for use in Odimma’s oncological neoantigen program. Through the deal, Odimma will gain access to […] December 7, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2022 Step Pharma and Concr to partner on cancer treatment Step Pharma, which works on CTPS1 inhibition for the targeted treatment of cancer, and Concr, a techbio company with a statistical learning-powered biomarker prediction engine, have entered a partnership to identify biomarkers to improve therapeutic response to inhibitors of cytidine triphosphate synthase 1 (CTPS1), an enzyme to which all cancers appear to be addicted. Concr’s […] December 7, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2022 BiVictriX identifies development lead for ADC cancer program BiVictriX Therapeutics plc, an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, has identified a development lead for its BVX001 program. The lead was developed using BiVictriX’s proprietary Bi-Cygni approach, which aims to generate the next-generation of antibody drug conjugates (ADCs) with superior […] December 7, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2022 INSPIRE launched to develop inhaled gene therapy for the treatment of lung cancer OmniSpirant Limited and EVerZom have launched INSPIRE, a €12.8 million ($13.4 million) lung cancer project funded by Horizon Europe. In one of the largest ever grants for preclinical research in lung cancer, OmniSpirant and its European partners in biotechnology, medical devices, cancer research, academia and patient advocacy, met in Galway, Ireland, for the official kick-off […] December 6, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2022 New brain tumor subtypes discovery may help develop treatments for incurable brain cancer Research led by RCSI University of Medicine and Health Sciences in Ireland has discovered three new subtypes of brain tumor. This could help to identify new and effective therapies. The novel tumor subtypes are forms of glioblastoma, the most common and most aggressive form of adult primary brain cancer with no cure currently available. The […] December 6, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2022 ImaginAb launching clinical trial for renal cancer and malignant melanoma ImaginAb Inc., which is focused on developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET) imaging agent and radiopharmaceutical therapy (RPT) products, is starting a phase II clinical trial. The trial, PRETZCEL, which will take place at Hull University Teaching Hospitals NHS Trust in the U.K., will investigate ImaginAb’s investigational CD8 ImmunoPET agent in patients with melanoma or […] December 6, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2022 Startup Graegis developing therapies for radiation side-effects Graegis Pharmaceuticals, a startup developing new therapies aimed at preventing the side effects of radiotherapies, is set to complete the regulatory nonclinical package allowing entry in clinical trials. The company, founded in the last quarter of 2021, spent the first year of operations running critical experiments on the new therapies, which will target radiation side […] December 6, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 5 Dec 2022 New company Liminatus Pharma Inc to develop three cancer treatments Clinical-stage biopharma company Liminatus Pharma LLC and Iris Acquisition Corp, a publicly traded special purpose acquisition company formed for the purpose of acquiring or merging with one or more businesses, announced they have entered into a definitive business combination agreement. Upon closing of the transaction, the combined company will be renamed Liminatus Pharma, Inc.. The […] December 5, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email